Barely Significant

Excerpts

514,629 sentences

highly significantp = 0.0310.6× alphaqualifiedgold
The expression of VEGF was absent in 4 (14.8%), weak in 16 (59.3%), mild in 4 (14.8%), and strong in 3 (11.1%) cases ( Table 2 ). The chi-square test revealed a highly significant difference in the expression of HIF-1α and VEGF between radicular cysts and periapical granulomas (chi-square test = 8.906, p = 0.031; chi-square test = 10.401, p = 0.015, respectively).
nominally significantp = 0.0310.6× alphagold
Similarly, ΔL3 was significantly increased when focusing on measurements deriving from the 800-g implants ( p = 2.98 × 10 –5 , Bonferroni adjusted p = 0.0002); whereas the Δ increase observed for 400-g implants was nominally significant, it did not pass multiple testing correction ( p = 0.031, Bonferroni adjusted p = 0.188).
an increasing trendP = 0.0310.6× alphagold
The fluctuation of plasma levels of IgA anti-CD74 over time in r-axSpA in comparison with the fluctuation in controls Mixed-effects analysis of log IgA anti-CD74 levels, adjusting for BMI and ever smoker (at inclusion in Backbone), revealed an increasing trend in relation to age in the controls (β = 0.11; 95% CI: 0.01, 0.2; P = 0.031).
marginally significantp-value = 3.1×10 −20.6× alphagold
Functional in silico analysis of 375 genes affected by protein-altering de novo variants (missense predicted as probably damaging by Polyphen, nonsense, conserved splice site (±2) and frameshift Indels) [20] , [21] , [22] , [23] and this study ( Table S5 ) revealed a marginally significant enrichment for genes involved in cellular component morphogenesis (GOTERM_BP_FAT Gene Ontology, Benjamini p-value = 3.1×10 −2 ) and genes expressed in brain tissues (TISSUE Expression, Benjamini p-value = 5.4×10 −8 ).
a decreasing trendP = 0.0310.6× alphagold
Women in their 30s, 40s, and 50s showed a decreasing trend of the prevalence of diabetes, and the prevalence of diabetes in women aged 30–59 years decreased significantly from 6.9% in 2001 to 4.5% in 2010 ( P = 0.031) ( Table 1 ).
close-to-significantp = 0.0310.6× alphagold
As shown in Figure 4 A, our results suggested a significant or close-to-significant increase in lymphocyte count ( p = 0.031) and PNI ( p = 0.017) and decrease in NLR ( p = 0.070) and PLR ( p = 0.079) in good prognosis patients, whereas the change in the poor prognosis group was insignificant, suggesting that the change in these immune cell parameters can early predict the efficacy of DPP4-inhibitor on the prognosis of post-operative patients.
a nonsignificant trendp = 0.0310.6× alphagold
A one-way repeated measures ANOVA revealed a significant main effect of condition, F (4, 71) = 42.34, p < 0.001, with significantly better performance for face and text than all other categories, all t > 6.4, p < 0.001, and no further significant differences, but a nonsignificant trend for eyes compared with noses, t (71) = 2.20, p = 0.031, all other t < 1.44, p > 0.15 ( Supplementary Figure S3 a).
nominally significantp = 0.0310.6× alphagold
A nominally significant difference was observed for bevacizumab at the 12-month landmark, favoring grade 2 over grade 3 (68.3% vs. 37.2%, p = 0.031); however, this isolated finding was not supported by a significant global log-rank comparison across grades ( p = 0.09) and was not consistently observed at other landmarks.
nominally significantp = 0.0310.6× alphagold
When we re-analyzed these associations in follow-up models using DNAm age residuals that did not account for estimated WBCs (i.e., only age, sex, and the first two PCs were regressed out of DNAm age estimates), we found that results for measured WBCs were unchanged, but results for CRP were nominally significant, though they missed our a priori corrected p -value threshold (β = 0.15, p = 0.031; Figure S4 ).
In the present study, the effects of upper- and lower-body exercise trials on fat oxidation rates on day 2 were comparable, although differences between the lower-body exercise and control trials did not reach statistical significance (upper-body exercise trial: ES = 0.459, 95%CI 0.00 to 0.03, P = 0.031; lower-body exercise trial: ES = 0.436, 95%CI –0.03 to 0.00, P = 0.061).